Mucin-Type O-Glycans: Barrier, Microbiota, and Immune Anchors in Inflammatory Bowel Disease
Yaqin Zhang,1,* Lan Wang,2,* Dickson Kofi Wiredu Ocansey,1,3 Bo Wang,1 Li Wang,4 Zhiwei Xu1 1Key Laboratory of Medical Science and Laboratory Medicine of Jiangsu Province, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, 212013, People’s Republic of China; 2Danyang Blood S...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/702ce4a8eacf4b2da29ff922a48af020 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:702ce4a8eacf4b2da29ff922a48af020 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:702ce4a8eacf4b2da29ff922a48af0202021-12-02T19:34:06ZMucin-Type O-Glycans: Barrier, Microbiota, and Immune Anchors in Inflammatory Bowel Disease1178-7031https://doaj.org/article/702ce4a8eacf4b2da29ff922a48af0202021-11-01T00:00:00Zhttps://www.dovepress.com/mucin-type-o-glycans-barrier-microbiota-and-immune-anchors-in-inflamma-peer-reviewed-fulltext-article-JIRhttps://doaj.org/toc/1178-7031Yaqin Zhang,1,* Lan Wang,2,* Dickson Kofi Wiredu Ocansey,1,3 Bo Wang,1 Li Wang,4 Zhiwei Xu1 1Key Laboratory of Medical Science and Laboratory Medicine of Jiangsu Province, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, 212013, People’s Republic of China; 2Danyang Blood Station, Zhenjiang, Jiangsu, 212300, People’s Republic of China; 3Directorate of University Health Services, University of Cape Coast, PMB, Cape Coast, Ghana; 4Huai’an Maternity and Children Hospital, Huaian, Jiangsu, 223002, People’s Republic of China*These authors contributed equally to this workCorrespondence: Li WangHuai’an Maternity and Children Hospital, 104 Renmin Road, Huaian, Jiangsu, 223200, People’s Republic of ChinaTel +86 135 1523 0755Email hafybjy@163.comZhiwei XuSchool of Medicine, Jiangsu University, 301 Xuefu Road, Zhenjiang, Jiangsu, 212013, People’s Republic of ChinaTel/Fax +86 511 8503 8215Email zhiweixu@ujs.edu.cnAbstract: Inflammatory bowel disease (IBD), which affects about 7 million people globally, is a chronic inflammatory condition of the gastrointestinal tract caused by gut microbiota alterations, immune dysregulation, and genetic and environmental factors. The association of microbial and immune molecules with mucin-type O-glycans has been increasingly noticed by researchers. Mucin is the main component of mucus, which forms a protective barrier between the microbiota and immune cells in the colon. Mucin-type O-glycans alter the diversity of gastrointestinal microorganisms, which in turn increases the level of O-glycosylation of host intestinal proteins via the utilization of glycans. Additionally, alterations in mucin-type O-glycans not only increase the activity and stability of immune cells but are also involved in the maintenance of intestinal mucosal immune tolerance. Although there is accumulating evidence indicating that mucin-type O-glycans play an important role in IBD, there is limited literature that integrates available data to present a complete picture of exactly how O-glycans affect IBD. This review emphasizes the roles of the mucin-type O-glycans in IBD. This seeks to provide a better understanding and encourages future studies on IBD glycosylation and the design of novel glycan-inspired therapies for IBD.Keywords: glycans, inflammation, intestinal mucus, MUC2, microbiota, immunityZhang YWang LOcansey DKWWang BWang LXu ZDove Medical Pressarticleglycansinflammationintestinal mucusmuc2microbiotaimmunityPathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 14, Pp 5939-5953 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
glycans inflammation intestinal mucus muc2 microbiota immunity Pathology RB1-214 Therapeutics. Pharmacology RM1-950 |
| spellingShingle |
glycans inflammation intestinal mucus muc2 microbiota immunity Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Zhang Y Wang L Ocansey DKW Wang B Wang L Xu Z Mucin-Type O-Glycans: Barrier, Microbiota, and Immune Anchors in Inflammatory Bowel Disease |
| description |
Yaqin Zhang,1,* Lan Wang,2,* Dickson Kofi Wiredu Ocansey,1,3 Bo Wang,1 Li Wang,4 Zhiwei Xu1 1Key Laboratory of Medical Science and Laboratory Medicine of Jiangsu Province, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, 212013, People’s Republic of China; 2Danyang Blood Station, Zhenjiang, Jiangsu, 212300, People’s Republic of China; 3Directorate of University Health Services, University of Cape Coast, PMB, Cape Coast, Ghana; 4Huai’an Maternity and Children Hospital, Huaian, Jiangsu, 223002, People’s Republic of China*These authors contributed equally to this workCorrespondence: Li WangHuai’an Maternity and Children Hospital, 104 Renmin Road, Huaian, Jiangsu, 223200, People’s Republic of ChinaTel +86 135 1523 0755Email hafybjy@163.comZhiwei XuSchool of Medicine, Jiangsu University, 301 Xuefu Road, Zhenjiang, Jiangsu, 212013, People’s Republic of ChinaTel/Fax +86 511 8503 8215Email zhiweixu@ujs.edu.cnAbstract: Inflammatory bowel disease (IBD), which affects about 7 million people globally, is a chronic inflammatory condition of the gastrointestinal tract caused by gut microbiota alterations, immune dysregulation, and genetic and environmental factors. The association of microbial and immune molecules with mucin-type O-glycans has been increasingly noticed by researchers. Mucin is the main component of mucus, which forms a protective barrier between the microbiota and immune cells in the colon. Mucin-type O-glycans alter the diversity of gastrointestinal microorganisms, which in turn increases the level of O-glycosylation of host intestinal proteins via the utilization of glycans. Additionally, alterations in mucin-type O-glycans not only increase the activity and stability of immune cells but are also involved in the maintenance of intestinal mucosal immune tolerance. Although there is accumulating evidence indicating that mucin-type O-glycans play an important role in IBD, there is limited literature that integrates available data to present a complete picture of exactly how O-glycans affect IBD. This review emphasizes the roles of the mucin-type O-glycans in IBD. This seeks to provide a better understanding and encourages future studies on IBD glycosylation and the design of novel glycan-inspired therapies for IBD.Keywords: glycans, inflammation, intestinal mucus, MUC2, microbiota, immunity |
| format |
article |
| author |
Zhang Y Wang L Ocansey DKW Wang B Wang L Xu Z |
| author_facet |
Zhang Y Wang L Ocansey DKW Wang B Wang L Xu Z |
| author_sort |
Zhang Y |
| title |
Mucin-Type O-Glycans: Barrier, Microbiota, and Immune Anchors in Inflammatory Bowel Disease |
| title_short |
Mucin-Type O-Glycans: Barrier, Microbiota, and Immune Anchors in Inflammatory Bowel Disease |
| title_full |
Mucin-Type O-Glycans: Barrier, Microbiota, and Immune Anchors in Inflammatory Bowel Disease |
| title_fullStr |
Mucin-Type O-Glycans: Barrier, Microbiota, and Immune Anchors in Inflammatory Bowel Disease |
| title_full_unstemmed |
Mucin-Type O-Glycans: Barrier, Microbiota, and Immune Anchors in Inflammatory Bowel Disease |
| title_sort |
mucin-type o-glycans: barrier, microbiota, and immune anchors in inflammatory bowel disease |
| publisher |
Dove Medical Press |
| publishDate |
2021 |
| url |
https://doaj.org/article/702ce4a8eacf4b2da29ff922a48af020 |
| work_keys_str_mv |
AT zhangy mucintypeoglycansbarriermicrobiotaandimmuneanchorsininflammatoryboweldisease AT wangl mucintypeoglycansbarriermicrobiotaandimmuneanchorsininflammatoryboweldisease AT ocanseydkw mucintypeoglycansbarriermicrobiotaandimmuneanchorsininflammatoryboweldisease AT wangb mucintypeoglycansbarriermicrobiotaandimmuneanchorsininflammatoryboweldisease AT wangl mucintypeoglycansbarriermicrobiotaandimmuneanchorsininflammatoryboweldisease AT xuz mucintypeoglycansbarriermicrobiotaandimmuneanchorsininflammatoryboweldisease |
| _version_ |
1718376387350364160 |